ViroLogic Vying For HIV Resistance Market Advantage As Rival Mulls Merger
This article was originally published in The Gray Sheet
Executive Summary
ViroLogic's new HIV replication assay will help drive conversion of the resistance testing market from genotype to phenotype-based tests, the firm believes
You may also be interested in...
VGI Trugene Interpretation Software Showcased At Seville HIV/AIDS Meeting
FDA's clearance process for future versions of Visible Genetics, Inc.'s HIV drug resistance assay interpretation systems may provide a key to how the agency will review next-generation genetic tests
VGI Trugene Interpretation Software Showcased At Seville HIV/AIDS Meeting
FDA's clearance process for future versions of Visible Genetics, Inc.'s HIV drug resistance assay interpretation systems may provide a key to how the agency will review next-generation genetic tests
ViroLogic
South San Francisco, Calif.-based biotechnology firm launches PhenoSense GT HIV drug resistance test Nov. 15. The test, which integrates ViroLogic's phenotypic assay PhenoSense HIV with the firm's genotypic assay GeneSeq HIV, is the "first HIV drug resistance test to provide doctors with a single report on a patient's drug resistance profile using phenotypic test results supplemented by genotypic information," according to the firm...